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The concept of a peptidomimetic was coined about forty years ago. Since then, an enormous effort 
and interest has been devoted to mimic the properties of peptides with small molecules or 
pseudopeptides. The present report aims to review different approaches described in the past to succeed 
in this goal. Basically, there are two different approaches to design peptidomimetics: a medicinal chemistry 
approach, where parts of the peptide are successively replaced by non-peptide moieties until getting a 
non-peptide molecule and a biophysical approach, where a hypothesis of the bioactive form of the peptide 
is sketched and peptidomimetics are designed based on hanging the appropriate chemical moieties on 
diverse scaffolds. Although both approaches have been used in the past, the former has been more widely 
used to design peptidomimetics of secretory peptides, whereas the latter is nowadays getting momentum 
with the recent interest in designing protein-protein interaction inhibitors. The present report summarizes 
the relevance of the information gathered from structure-activity studies, together with a short review on 
the strategies used to design new peptide analogs and surrogates. In a following section there is a short 
discussion on the characterization of the bioactive conformation of a peptide, to continue describing the 
process of designing conformationally constrained analogs producing first and second generation 
peptidomimetics. Finally, there is a section devoted to review the use of organic scaffolds to design 





Peptides are not only important mediators in the regulation of many physiological processes 
eliciting actions as hormones, neurotransmitters, neuromodulating agents or immunomodulators, but also 
can act as antagonists, enzyme inhibitors or protein-protein disruptors, blocking the transduction of diverse 
signals. This wide spectrum of activities makes peptides attractive molecules for pharmaceutical 
intervention. Despite the plethora of pharmacological actions exhibited, only a small number of peptides 
are currently in the market due to their poor oral bioavailability, low absorption, rapid degradation by 
proteolytic enzymes and immunogenic profile [1]. This poor pharmacokinetic profile requires their nasal or 
parenteral administration.  
Most peptides presently approved for therapeutical intervention are agonists, being used in 
substitution therapy with well-known examples like oxytocin for inducing or augment labor; parathynoid 
hormone for the treatment of osteoporosis; luteinizing hormone releasing hormone for the treatment for 
infertility; the segment 17-36 of the glucagon-like peptide-1 for the treatment of diabetes; peginesatide an 
erythropoietin peptide surrogate for the treatment of anemia associated with chronic kidney disease; 
somatostatin used in acromegaly and neuroendocrine tumor therapy; gastrin-releasing peptide used for 
cancer treatment or calcitonin for the treatment of osteoporosis [2]. In contrast, the number of peptide 
analogs used as blocking agents is much lower. There are a few antagonists like icatibant, a bradykinin B2 
antagonist used for the symptomatic treatment of acute attacks of hereditary angioedema in adults with 
C1-esterase-inhibitor deficiency [3] or saralasin, an angiotensin II antagonist used for the treatment of 
hypertension [4]. There are also a few peptide analogs used as enzyme inhibitors like enapril, an inhibitor 
of the angiotensin converting enzyme used as antihypertensive drug [5] or bivalirudin, a hirudin analog 
inhibitor of thrombin used as an anticoagulant in patients with unstable angina undergoing percutaneous 
transluminal coronary angioplasty [6]. Finally, there are only a few peptide analogs in the market acting as 
protein-protein disruptors, like cyclosporin A an immunosuppressant drug used in organ transplantation to 
prevent rejection [7] or the antiviral enfuvirtide, a segment of the transmembrane protein gp41 of the HIV 
that inhibits fusion of the viral envelope and host cell membrane [8]. In addition, there is a large number of 
promising molecules in this group of peptides presently under development like the series of peptide 
analogs containing the RGD recognition motif with antithrombotic profile [9] or, the recently developed 
series of Bak-BH3 analogs, compounds that enhance apoptosis through the inhibition of the Bcl-xL protein 
and used as anticancer drugs [10].  
Two major approaches have been used in the past to surmount the poor pharmacokinetic profile of 
peptides. One consists in the use of pseudopeptides [11, 12] and cyclic analogs [13] designed to be 
resistant to proteolytic degradation and endowed with improved bioavailability. Recent advances in this 
area along with the development of new delivery procedures [14] make this approach very promising [15]. 
The other approach consists of designing small molecules -so called peptidomimetics- that mimic the 
steric and chemical features of bioactive peptides. The procedure to design peptidomimetics is not unique 
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and there are diverse strategies described in the literature that combine medicinal chemistry and modeling 
methodologies in different proportions. The focus of the present review is to provide a brief summary of 
the diverse strategies described in the literature devoted to design peptidomimetics. The reader is also 
invited to review previous reports published in the literature on the topic [16-29]. 
The concept of peptidomimetic was coined about forty years ago when the long time postulated 
endogenous opioid enkephalin was discovered in the middle of the seventies (actually two different 
enkephalin analogs were isolated: Met-enkephalin and Leu-enkephalin with a similar pharmacological 
profile) [30]. The existence of enkephalins had been long time postulated as an explanation for the known 
pharmacological actions of morphine. The characterization of the enkephalins provided for the first time 
the opportunity to compare a peptide sequence with the chemical structure of the small molecule exerting 
the same pharmacological action. Indeed, comparison of the two structures led to the identification of 
specific common steric and chemical features that were assumed to be requirements for the μ-opioid 
receptor activation, boosting the concept that the biological action of morphine was due to its ability to 
mimic the bound conformation of enkephalin [31]. This opened the door to the fascinating area of 
peptidomimetic research full of successful stories.   
Peptidomimetic design requires as first step the establishment of solid structure-activity 
relationships that permits the identification of those residues important for peptide recognition and 
activation. This involves knowledge of the minimum peptide length that preserves biological activity, 
together with a list of peptide analogs with known biological activity. To construct this list, analogs can be 
designed by modification of the peptide backbone or by side chain replacement. Once a solid structure-
activity relationships is established, the design of a peptidomimetic requires specific knowledge about the 
features of the bioactive conformation that can be inferred either from spectroscopic analysis and/or 
computational methods. These two sources of information provide the grounds to produce a first 
generation of peptidomimetics. For this purpose two different approaches can be followed, as displayed in 
Figure 1. The first is a medicinal chemistry approach that involves the synthesis of conformationally 
constrained analogs aiming at mimicking the features of the bound conformation. This is carried out either 
through the synthesis of diverse analogs incorporating conformationally constrained amino acids in 
different positions or through the synthesis of analogs that incorporate organic scaffolds replacing two 
consecutive residues. First generation peptidomimetics are hybrid molecules that are in part peptide and 
in part small molecule with improved pharmacokinetic properties in regard to the parent peptide. After 
evaluation of their biological activity they are used as the starting point to develop second generation 
peptidomimetics, i.e. small molecule-like compounds. Combinatorial chemistry can be a helpful strategy to 
be used at this step. Alternatively, peptidomimetic design can be performed involving the use of 
computational chemistry tools used to sketch features of the bioactive conformation [32]. These studies 
combined with the information gathered from structure-activity relationships studies can be used to 
develop a pharmacophore defining the steric and electronic features necessary to ensure the optimal 
supramolecular interactions with the target macromolecule [33]. The pharmacophoric hypothesis can be 
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subsequently used as a query in virtual screening to search for hits in diverse data bases [34]. 
Alternatively, it can also be used as a template to design new molecules that fulfill the pharmacophoric 
hypothesis using diverse chemical scaffolds.  
Structure-Activity Relationships Studies 
It is a well-established paradigm in chemistry that the physicochemical properties of molecules as 
well as their biological activities are related to their structure. Advances in understanding the connection 
between structure and physicochemical properties or biological activity of molecules have always gone 
hand in hand, stressing their intrinsic connection [35]. The establishment of structure-activity relationships 
in peptides requires an understanding of the importance of the N- and C-terminal groups for activity; the 
minimum peptide segment preserving function and identification of specific residues responsible for 
conferring biological activity to the peptide. Actually, there are a number of naturally occurring peptides 
that see their activity modified upon modifications of the terminal groups. Thus for example, C-terminus 
amidation is a common posttranslational modification that can be key for the activity of a peptide. For 
example, the C-terminus of substance P needs to be amidated to exhibit activity [36]. Another important 
piece of information regards the shortest fragment of the peptide retaining biological function. Indeed, 
since peptides are large molecules, they may interact with a receptor through diverse anchoring points. 
Knowledge of the shortest fragment retaining biological function is important to set boundaries for 
designing a mimetic. There are diverse examples of bioactive peptides where a specific biological activity 
is associated to a short fragment. Thus, for example the sequence of Met-enkephalin (Tyr-Gly-Gly-Phe-
Met) is the shortest sequence within the family of opioid peptides retaining full activity and corresponds to 
the five residue N-terminal end of β-endorphin, a larger endogenous opioid [37]. Similarly, the four residue 
C-terminal segment of cholecystokinin known as CCK-4 (Trp-Met-Asp-PheNH2), represents the shortest 
fragment of the native peptide retaining full activity [38]. 
Once the smallest active fragment is identified and peptide termini characterized, it is necessary to 
identify what residues are key for peptide activity. For this purpose a series of analogs are synthesized 
and their biological activity tested. Analogs produced at this step are the result of conservative changes. 
One procedure to follow consists of testing the effect of deleting one or more consecutive amino acid(s) or 
even a combinatorial deletion of two or more positions throughout the sequence. Similarly, analogs 
produced by changing the order of two residues in the sequence sometimes provide information about the 
importance of a specific side chain. Another procedure utilized consists of replacing a residue by its D-
amino acid enantiomer, providing information about the importance of the stereochemical requirements of 
a residue side chain [39]. Alternatively, a systematic replacement by alanine in each of the residues of the 
polypeptide chain is also a standard procedure to gather information about the role played by the diverse 
residues on the activity of the peptide [40]. Alanine substitutions are not expected to change dramatically 
the intrinsic conformational features of the polypeptide chain, but can provide information about how the 
diverse nature of the side chains is involved in receptor recognition. Table 1 shows as an example the 
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alanine scan of the sequence Gly1-Gln2-Val3-Gly4-Arg5-Gln6-Leu7-Ala8-Ile9-Ile10-Gly11-Asp12-Asp13-Ile14-
Asn15-Arg16, an inhibitor of the protein Bcl-xL that is involved in the apoptosis process [41]. As it can be 
seen, most of the replacements produce a remarkable effect on the affinity of the ligand, being at Leu7 the 
replacement that produces the most dramatic effect. In contrast, replacement of residues Ile9, Gly11 and 
Asp13 does not produce a significant change in the affinity of the ligand. Actually, the NMR structure of the 
peptide bound to Bcl-xL provides an explanation to this result since these residues are solvent exposed 
[41]. The alanine scan provides information about the relative importance of the diverse residues in the 
sequence for affinity and activity that can be used as guide for the synthesis of new analogs.  
In a subsequent step, new peptide analogs can be designed modifying the peptide backbone or 
through side chain replacement. Biological evaluation of these analogs may provide information on the 
relevance of specific residues and reveals information about the features of the peptide-receptor 
recognition interface. However, it should be borne in mind that modifications on the peptide structure may 
also alter its conformational profile, impairing its ability to attain the bioactive conformation. Modifications 
of the peptide backbone include N-methylation of the nitrogen amide 1 in Figure 2 [42] and reduction of 
the peptide bond producing methylene amino derivatives 2 in Figure 2 [43]. Both procedures produce 
peptide analogs with a reduced capability to undertake hydrogen bond interactions. Moreover, partial or 
total removal of the hydrogen bond capabilities of the peptide bond also reduces hydration making the 
compounds more suited to membrane penetration. Actually, reduction of the peptide bond is a specific 
case of a more general class of modifications known as isosteric replacements, where the peptide bond is 
substituted by an equivalent chemical group, as will be discussed later [44]. Alternatively, production of 
analogs designed by side chain replacement provides insights into the kind of interaction the side chain is 
involved with its receptor. For example, replacement of a tyrosine by a phenylalanine provides information 
about the role of the hydroxyl group of the phenyl moiety, whereas replacement by a hydrophobic residue 
like leucine by phenylalanine provides information about the requirement of an aromatic moiety at this 
position.  
Peptide Bond Isosteric Replacement 
Biosiosteric replacement represents a rational approach for the modification of lead compounds 
into safer and more clinically effective agents. The procedure provides a guide to design new analogs of a 
given compound through substitution of specific chemical moieties by other functional groups (isosteres) 
that have chemical and physical similarities producing broadly similar biological effects [45].  
According to the original definition by Langmuir [46], isosteres are atoms, ions and molecules that 
have identical valence electrons and expected to exhibit similar physicochemical properties. Thus for 
example, the sodium ion (Na+) and the hydrogen ion (H+), are isosteric ions with no valence electron left 
or, carbon dioxide (CO2) and nitrous oxide (N2O) are isosteres both with sixteen valence electrons. This 
definition was extended later to include molecules and chemical moieties molecules in which the 
peripheral layer of electrons can be considered identical. So, for example methyl, amine and hydroxyl 
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groups are isoteres since the three groups exhibit seven valence electrons. The concept of isosterism was 
broadened a few years later to include chemical groups that possess near-equal molecular shapes and 
volumes, approximately the same distribution of electrons, and which exhibit similar physical properties 
[47]. 
Peptide bond isosteric replacement is a procedure aimed at designing peptide analogs close to the 
parent peptide endowed with improved resistance to proteolytic cleavage through peptide bond 
replacement using peptide bond surrogates. However, caution should be exercised since these 
modifications affect the chemical features of the peptide bond and moreover, they may also influence the 
conformational profile of the peptide and consequently, its affinity. This procedure has been demonstrated 
in the past to be good strategy to design first generation peptidomimetics and, especially suitable in 
designing protease inhibitors. Specifically, in this case since the bioactive conformation is mostly extended 
a simple isostere replacement of the scissile bond usually provides an active compound, although not 
necessarily with higher affinity than the original peptide. A recent story of successful use of isostere 
replacement as strategy for drug design can be found in the publications that led to the design of a first 
generation of HIV protease inhibitors [48]. 
 
Figure 2 shows the chemical structures of typical peptide bond isosteres. A conservative 
replacement of the amide peptide bond consists of the substitution of the carbonyl oxygen by a sulfur atom 
to yield a thioamide isostere 3 (Figure 2). The substitution of oxygen to sulfur increases the rotational 
barrier around the peptide bond by 2-3 kcal/mole, making these analogs good inhibitors of peptidylprolyl 
isomerases, enzymes that catalyze the rotation across the peptide bond. On the other hand, this isostere 
exhibits a higher dipole moment than the corresponding amides and consequently, it is a suitable 
substitution to incorporate in helical structures, although the sulfur atom of thioamides is a poor hydrogen-
bond acceptor [49]. In medicinal chemistry, thioamide analogs of antibiotic peptides represent a successful 
example of the potential use of this isostere in the design of peptidomimetics [50]. 
The replacement of the peptide amide nitrogen by oxygen or sulfur generates an ester 4 (Figure 2) 
and a thionoester isosteres 5 (Figure 2), respectively. In this case, although rotational barriers are lower 
compared to those of the amides, electron delocalization provides a partial double bond character to the 
ester bond so that both, cis and trans conformations are attainable [51]. From the structural point of view, 
esters exhibit higher torsional flexibility than amides and moreover, they are deprived of the hydrogen 
bond capability as donors, with an accepting hydrogen bond capability of the carbonyl group weaker than 
in the case of the amide group. All this, together with the fact that they are vulnerable to hydrolysis makes 
them less attractive for peptidomimetic design. Peptides that have at least an ester link between two 
amino acids are referred as depsipeptides. In fact, there is a number of naturally occurring cylic 
depsipeptides with a variety of pharmacological profiles, like actinomycin that exhibits antibiotic activity 
[52] or romidepsin with a cytotoxic profile currently undergoing clinical trial as anticancer drug for the 
treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma [53]. 
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Replacement of the nitrogen by a carbon produces a ketomethylene isostere 6 (Figure 2). In this 
case the cis/trans constraint associated to the peptide bond is lifted. The ketomethylene isostere has been 
successfully used to design renin [54] and HIV protease inhibitors [55]. Moreover, its alpha carbon can be 
substituted further by a fluor, producing α-fluoroketone isosteres 7 (Figure 2). These isosteres contain 
fluorine-activated electrophilic carbonyl groups that react readily with active site nucleophiles such as 
hydroxyl groups in serine proteases, thiol groups in cysteine proteases or, water in aspartate and 
metalloproteases to produce transition-state analogues in the active site [56]. 
Alternatively, the carbonyl group can be replaced by similar chemical groups using other 
heteroatoms, like sulfur in the case of the sulfonamide 8 (Figure 2), sulfonate 9 (Figure 2) or phosphorous 
in the case of phosphonamide 10 (Figure 2), phosphonate 11 (Figure 2), phosphothionate 12 (Figure 2) or 
phosphinate 13 (Figure 2). These isosteres exhibit a tetrahedral configuration making them suitable to act 
as transition state analogs. Considering their structures, sulfonamides and sulfonates produce a significant 
twist in the backbone chain in comparison to the amide bond, due to the difference on dihedral angle 
adopted (from a 180º of the amide bond to a 90º of the sulfonamide) necessary to preserve delocalization 
of π electrons. The sulfonamide NH is relatively more acidic than that of the amide moiety, and thus is a 
strong hydrogen bond donor.  
Another possibility to produce peptide bond isosteres is the reduction of the amide carbonyl to an 
alcohol. These isosteres can be considered as transition state analogs, since proteolysis occurs through a 
tetrahedral intermediate. If the nitrogen amide is preserved the isostere obtained is hydroxylamine 14 
(Figure 2), and if the nitrogen is replaced by carbon we obtain hydroxyethylene 15 (Figure 2) and well as 
dihydroxylethylene 16 (Figure 2). For example, aliskiren is a potent inhibitor of renin for the treatment of 
hypertension is a hydroxyethylene isostere, substituted at the cleavage site [57]. 
Amide carbonyls can be further reduced to obtain methylene amino isosteres 2 (Figure 2) and 
derivatives, like the trifluoroethylamino isosteres 17 (Figure 2). These isosteres exhibit higher 
conformational flexibility due to the loss of the partial double character of the amide bond. The former 
compounds have been used in the development of agonists of cholecystokinin [58] and somatostatin [59] 
or antagonists of bombesin [60]. The latter compounds are interesting isosteres since the trifluoromethyl 
moiety is isopolar to the carbonyl group. Another interesting feature of these isosteres is the decreased 
basicity of the amine without compromising the ability of the NH to function as a H-bond donor. The 
methyleneamino moiety has recently been used with success for designing inhibitors of Pin1, a peptidyl-
prolyl isomerase involved in cis−trans isomerization of Xaa−Pro amide bonds [61]. Odanacatib, currently 
in phase III clinical trials is a nice example of analog containing a trifluoroethylamino isostere. This 
compound acts as an inhibitor of cathepsin K, preventing calcium resorption to be used for the treatment 




Substitution of the amine nitrogen by oxygen or sulfur produces derivatives like the methyleneoxy 
18 (Figure 2) or the methylenemercapto 19 (Figure 2), respectively. 
Alkanes can also be considered as isosteres of the peptide bond 20 (Figure 2). However, more 
interesting are when they are reduced to alkenes 21 (Figure 2) and their derivatives like fluoroalkenes 22 
(Figure 2) and difluroalkenes 23 (Figure 2). These isosteres preserve the planarity of the peptide bond and 
the cis/trans isomerism associated. Alkenes are a better substitutes of the peptide bond, although exhibit 
smaller dipole moments and have lost their ability to participate in hydrogen bonding. These differences 
have consequences in the structural features of the peptide sequences they participate. Thus, for example 
they are expected to be helical structure disruptors. Moreover, the cis isomer in dipeptides Xaa-Pro is 
more stable, reducing their capability to participate in β-turns [63]. Examples of the use of this isostere can 
be found in diverse analogs of substance P [64] or in the CXCR4 chemokine receptor antagonist FC131 
[cyclo(-D-Tyr-Arg-Arg-Nal-Gly-), Nal = 3-(2-naphthyl)-alanine] [65]. Further reduction yields alkyne 24 
(Figure 2) that can also be used as peptide bond isostere. 
Other isosteres that recover the amide group at the expense of losing the alpha carbon are the 
hydrazine 25 (Figure 2) and the amideoxy 26 (Figure 2). 
There are also cyclic isosteres that can be aromatic, although usually are partially or completely 
saturated rings. Typical cyclic isosteres include carbacycles 27 (Figure 2), azacycles 28 (Figure 2) and 
oxacycles 29 (Figure 2).  
Pseudopeptides  
This is a group of molecules designed to avoid protease degradation while preserving peptide 
sequence. Peptide analogs in this group include retro-inverso peptides, peptoids and β-peptides.  
Retro-inverso peptide analogs consist of polypeptides in which the direction of one or more peptide 
bonds is reverted with a concomitant change of the configuration of the following alpha carbon of the 
polypeptide chain 30 (Figure 3) [66, 67]. It can be distinguished between totally modified retro-inverso 
analogs when all the peptide bonds of the parent peptide are reversed and to partially modified retro-
inverso analogs when one or more peptide bonds are reversed. These compounds exhibit an improved 
resistance to proteolytic hydrolysis and in many cases, with retention of their biological activity. Due to 
their improved pharmacokinetic profile these peptide surrogates can be used as therapeutic agents. A 
recent example is the totally modified retro-inverso analog of the peptide OR2 that shows promising 
results for the treatment of Alzheimer's disease. OR2 is a decapeptide with sequence Asn-Arg-Gly-Lys-
Leu-Val-Phe-Phe-Gly-Arg-NH2 with inhibitory activity against the aggregation of beta-amyloid. Aimed at 
finding peptide surrogates of OR2 with improved pharmacokinetic profile, the total retro-inverso analog RI-
OR2 was synthesized and proved to be as active as the template and highly stable to proteolysis [68]. Due 
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to its pharmacological profile this analog will permit to pursue further experiments and demonstrate the 
efficacy of this therapy for the treatment of Alzheimer's disease. 
Peptoids represent another variant to construct molecules using polypeptides as a source of 
inspiration with improved pharmacokinetic profile. Peptoids can be considered as polymers of N-
substituted glycines, so that they look like peptides but with the side chains attached to the backbone 
amide nitrogen instead to the α-carbon 31 (Figure 3) [69, 70]. The simplest member of the family is 
sarcosine (N-methylglycine), a naturally occurring amino acid found in muscles and other body tissues. 
From the pharmacological point of view, sarcosine is a competitive inhibitor of the type I glycine 
transporter and an N-methyl-D-aspartate receptor (NMDAR) co-agonist [71]. Peptoids exhibit an increased 
flexibility compared to regular peptides due to the achirality of the α-carbon that provides a large range of 
allowable φ and ψ angles and the presence of a tertiary amide bond since both the cis and trans 
conformations of the peptide bond are possible. These features may decrease the affinity of ligands 
compared to their parent peptides due to the entropic penalty paid upon binding to its receptor. Another 
structural feature of peptoids is their inability to form intramolecular hydrogen bonds through backbone–
backbone interactions, because of the lack of amide hydrogens. Despite their limitations, peptoids can be 
driven to form helical secondary structures through a periodic incorporation of bulky, α-chiral side chains. 
From the pharmacokinetic point of view, N-alkylation, in particular methylation provides these molecules a 
reduced biodegradation profile since tertiary amides are more resistant to proteolytic degradation [72]. 
Moreover, they also exhibit increased bioavailability due to the lack of hydrogen donors favoring cell 
penetration. Accordingly, diverse peptoids with cell-penetrating properties and antimicrobial activities, as 
well as mimics of lung surfactant proteins have been reported [73]. Furthermore, ligands based on 
peptoids often containing a single α-amino acid have been shown to have superior cell-penetrating 
abilities compared to the corresponding peptides [74].  
A different strategy to construct pseudopeptides consists of using β-amino acids. These molecules 
are amino acids that have the amino group attached in beta position relative to the carbonyl group. There 
are two types of β-amino acids depending on the position of the side chain. When the side chain is 
attached to the carbon in alpha are called β2 32 and β3 when the side chain is attached to the carbon in 
beta 33 (Figure 3). Peptides constructed with these amino acids preserve all the chemical characteristics 
of natural peptides, but the addition of an extra methylene group to the backbone chain provides stability 
against peptidase degradation [75]. Moreover, analogs composed of alternating α- and β-amino acids 
residues are also very resistant toward degradation [76]. The only beta amino acids found in nature is 
beta-alanine, a component of the naturally occurring peptides carnosine and anserine, potent scavengers 
of reactive oxygen species as well as alpha-beta unsaturated aldehydes formed from peroxidation of cell 
membrane fatty acids during oxidative stress [77]. Although the addition of an extra methylene to the 
backbone chain adds certain flexibility to the molecule, β-peptides can adopt secondary structures like 
natural peptides [78, 79]. Knowledge of the secondary structure trends shown by this kind of amino acids 
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have been used to design amphipathic peptides that exhibit interesting properties as antibacterial agents 
[73]. 
The Bioactive Conformation  
In addition to understand the chemical groups and peptide features important for activity as 
deduced from the structure-activity studies, knowledge of the features of the bioactive conformation is also 
necessary for designing peptidomimetics. The conformation attained by a flexible ligand when bound to its 
target macromolecule is known as the bioactive conformation. The binding process of a ligand to its target 
macromolecule is governed by the molecular interactions between the ligand and the residues involved in 
defining the binding site. At long distances electrostatic interactions are predominant, but at short 
distances the diverse contributions become comparable, so that the peptide finally adopts the 
conformation with the lowest energy within the environment of the target macromolecule. The affinity of a 
ligand for its target macromolecule Ka is related to the free energy of binding according to the relation 
ΔGo=-RTlnKa. The free energy has an enthalpic and an entropic contribution. The former contribution 
accounts for the favorable interactions between the peptide and the macromolecule, as well as for the 
energy penalty suffered by the peptide and/or the protein for not being in their lowest energy 
conformational state. On the other hand, the latter accounts for the loss of peptide configurational entropy 
upon binding to its target macromolecule [80]. It should also be taken into account a free energy 
associated to the desolvation/solvation process that includes both enthalpic and entropic contributions. 
There are two limiting mechanisms to describe the ligand-protein recognition step. On the one 
hand, the conformational selection, also called population shift mechanism by which a peptide approaches 
in its bioactive conformation and fits into the binding site of the protein, like in the lock-and-the-key model 
[81]. On the other hand the induced fit mechanism, where the conformation of the peptide and the binding 
site of the protein simultaneously adapt to each other, like a glove to a hand [82]. However, there are 
indications suggesting that peptide binding may proceed through a combination of the two mechanisms. 
This idea has been explored in a recent report where a set of peptides with known bound conformation 
were docked into the corresponding target proteins using a mixed procedure that combines conformational 
selection and induced fit, achieving a 75% success rate in the prediction of the experimental results [83]. 
When the bioactive conformation is known, the mimicry process for designing peptidomimetics can 
be carried out by chemical group substitutions, restricted to preserve the overall geometry and taking into 
account the key residues for activity. Nowadays there are around 500 unique protein-peptide complexes 
determined by X-ray diffraction and NMR spectroscopy studies deposited in the protein data bank (pdb) 
[84] and compiled in the Pep-X data base [85]. Complexes include a few enzyme-inhibitor complexes, 
peptide-signaling proteins, antibody-antigen complexes and hormone-receptor complexes. Analysis of the 
structures of peptide-signaling proteins, as well as those of enzyme-peptide complexes with those of 
monomeric proteins, suggests that peptide ligands adopt conformations complementary to the tertiary 
structure of the binding domain. In other words, ligands adopt the conformation expected to attain as if 
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they were a protein segment [86]. This finding opens the possibility to identify new linear regulatory motifs 
from the analysis of the 3D structure of the effector protein [87]. Moreover, peptide segments with the 
same sequence may adopt different secondary structures in diverse proteins like in the case of the 
segment NAAIRS that adopts a helical structure in phosphofructokinase and an extended conformation in 
thermolysin. Consequently, it is expected that the bound conformation of a peptide may be different for 
diverse target proteins.  
Peptides can act as substrates of enzymes. The vast majority of peptides are substrates of 
proteases that catalyze the cleavage of a peptide bond very efficiently. There are two broad classes of 
proteases: those that use water as nucleophile to mediate the hydrolysis of the peptide bond, like aspartic 
and metalloproteases, and those that use the side chain of specific residues to produce the nucleophilic 
attack, like in serine, threonine and cysteine proteases, named after the residue involved. In this case, an 
acyl-enzyme intermediate is produced that is subsequently hydrolyzed by water to complete the hydrolysis 
process. Ligases represent another class of enzymes that use peptides as substrates. These enzymes 
attach a chemical moiety to the peptide chain mediating posttranslational modifications.  
The catalytic efficiency of enzymes is due to their capability to stabilize the transition state, lowering 
the activation free energy of the reaction [88]. As a consequence enzymes are designed to have a high 
affinity for transition state analogs [89]. This strategy has been used for drug design constituting an ample 
class of peptidomimetics [90]. The efficiency of these enzymes achieved though evolution makes that the 
time necessary to study them using X-ray diffraction or NMR spectroscopy studies is much shorter than 
the time necessary to process the substrate. Accordingly, most of the complexes of peptide-enzyme are 
inhibitors, rather than substrates. Protease cleavage sites are frequently located in flexible solvent-
exposed loops, although a number of sites have also been identified in α-helix structures. In general, 
enzyme binding sites are flexible regions, result that explains why only a few structures have been solved 
that include residues encompassing the cleavage site [91]. Inhibitors mostly bind in extended 
conformations like the HIV protease inhibitors (pbd entry 2FNT), although bent structures like the 
urokinase plasminogen activator inhibitor (entry 1GJB) can also be found. Some peptides exhibit a helical 
structure like calpain inhibitors (pdb entry 1NX1) and even hairpin structures like in the beta trypsin 
inhibitor (pdb entry 1SBW). 
In the case of regulatory peptides, they adopt mostly an extended conformation and in a few cases 
helical structures. The trends observed in this class of peptides are the same those observed in enzymes-
peptide complexes. Thus for example, in the complex of the signaling Traf2 with a segment of CD40 (pdb 
entry 1QSC) the peptide is found in an extended conformation, whereas in the complex of the anti-




Other important group of cell signaling peptide-protein complexes is those of short antigenic 
peptides bound to the major histocompatibilty complex (MHC) class I and II proteins that are subsequently 
presented to the appropriate T-cell receptors. In this case peptides appear in an extended conformation 
(pdb entry 1SYV) [92]. Similarly, peptides binding to the ATP-binding cassette transporter associated with 
antigen processing (TAP) bind in an extended kinked structure, analogous to those bound to MHC class I 
proteins [93]. 
In the case of antigen-antibody complexes, most of the structures reveal the antigen adopting a β-
turn motif and deeply embedded in the antibody-antigen interface [94]. Interestingly, in this case the bound 
structures of the antigens do not necessarily correspond to those on the original epitope, since in most of 
the cases the anti-peptide antibodies do not bind to the native protein. Thus, for example in 
myohemerythrin the epitope of sequence EVVPHKK exhibits a helical structure [95], whereas when bound 
to the monoclonal antibody B13I2 exhibits a type II β-turn [96]. 
In the case of hormones, some of the peptides are longer than 30 residues and adopt folded 
conformations, being the simplest the α-helix conformation [85]. Also within this group of peptides, the 
structure of [8-13]neurotensin has been recently crystallized bound into its receptor, a G-protein coupled 
receptor [97].  In the complex, the peptide is shown to adopt an extended conformation, with the C-
terminus buried in the orthosteric site, whereas the N-terminus faces the surface, in agreement with 
previous solid state NMR spectroscopy studies [98]. In this case, the peptide adopts a structure similar to 
the one found by NMR in solution under the influence of structuring solvents [99]. The nonapeptide 
bradykinin bound to the B2 receptor is another example of a peptide bound to a GPCR whose structure 
was solved by solid state NMR spectroscopy [100]. In this case, the peptide exhibits a distinct double S 
shape with a β-turn on its C-terminus. 
Unfortunately, detailed information of the bioactive conformation is not available most of the time. 
Instead, sketchy information of the bioactive conformation can be obtained from spectroscopic methods or 
computer simulations, basically a secondary structure motif on the peptide segment [101]. In this case, the 
strategy followed for peptidomimetic design consist of producing conformationally constrained analogs 
aimed at reinforcing any hypothesis about a specific secondary structure motif present in the bioactive 
conformation [102]. However, rigidified analogs may or may not exhibit any conformational feature of the 
bioactive conformation. In the case they do, they are expected to have an increased binding free energy to 
the target protein due to the bioactive conformation population enhancement and a concomitant reduction 
of the entropic loss penalty upon binding. To guide this process it is necessary the use of spectroscopy 
and/or computational studies that provide information about the secondary structure of the peptide. 
However, caution should be exercised since the conformation a peptide attains in solution is not 
necessarily related to the bioactive conformation.  
Rigidification makes peptides less flexible and therefore more pre-organized, displaying a higher 
affinity compared to linear counterparts, due to the enhancement of specific secondary structure motifs 
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and to the reduction of the entropy cost upon receptor binding. This in turn provides peptide analogs with 
increased potency; more resistant against proteolytic degradation; increased selectivity and enhanced 
bioavailability. A simple procedure to rigidify the structure of a peptide and simultaneously enhance 
specific secondary structure motifs is cyclization [103]. As an alternative to cyclization, rigidified analogs 
can also be produced by replacement of specific amino acids of the sequence for non-coded 
conformationally constrained amino acids [104]. 
The Medicinal Chemistry Approach 
Globally Constrained Analogs 
Cyclization increases peptide resistance to proteases degradation as well as cell permeability and 
leads to exceptional physicochemical stability, so that cyclic peptides constitute an important class of 
therapeutic peptides [105, 106]. Cyclic peptides can be formed via backbone (head-to-tail cyclization); via 
linkage of side chain functionality to the N-/C-terminus; or via the linkage of a side chain to another side 
chain [107]. In this latter case there is a diversity of structures possible, including macrocyclic disulfides 
formed by two cysteines, thioethers, lactams or lactones. Cyclization can also be formed through an ester 
bond giving rise to a series of compounds known as cyclic depsipeptides. Figure 4 displays different 
possibilities of peptide cyclization. Giving this versatility to produce cyclic peptides, cyclization can be used 
to produce a global conformational constraint on the peptide or just produce a local constraint when 
cyclization occurs in a short segment of the peptide.  
Proof of the relevance of cyclic peptides as drug candidates comes from the fact that most of the 
peptides produced by diverse organisms for predation, defense or competitor deterrence are cyclic. 
Actually, these are compounds designed to produce a physiological response on a guest organism and 
consequently they require having improved pharmacokinetic properties. Cyclic peptides found in nature 
exhibit diverse pharmacological activities, including antibiotic, immunosuppressive, cytotoxic or neurotoxic. 
For example, a paradigmatic example of antibiotic peptide is the vancomycin [108]. It is a bicyclic peptide 
formed via side-chain/side-chain cyclization and represents an example of a comparatively rare halo-
organic natural compound. Vancomycin is naturally produced by a species of the actinobacteria, a group 
of Gram-positive bacteria found in soil. Cyclosporin A is a paradigmatic example of immunosuppressive 
drug extensively used in organ transplantation to prevent rejection [109]. Cyclosporin A is a cyclic 
undecapeptide with the cycle closure formed by a lactam. The peptide has few non-proteinogenic 
residues, including a D-Ala in position 8, although its most important differential feature is that seven out of 
the eleven residues are N-methylated. Keramamide F is a cylic heptapeptide found in marine sponges of 
the genus Theonella with cytotoxic activity [110]. The peptide contains non-proteinogenic amino acids 
such as (O-methylseryl)thiazole, α,β-dehydrotryptophan, isoserine, 2,3-diaminopropionic acid, and 3-
amino-4-methyl-2-oxohexanoic acid and cyclization occurs through the link of the side chain of the 2,3-
diaminopropionic acid to the C-terminus through a lactam bond. Finally, there are cyclic peptides among 
the toxins produced by cyanobacteria, including the microcystins and nodularins [111]. These compounds 
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are inhibitors of the protein phosphatase type 1 and type 2A, leading to an increase in phosphorylation of 
proteins in liver cells. Microcystins are cyclic heptapeptides that contain diverse non-proteinogenic amino 
acids, such as the β-amino acid (2S,3S,8S,9S,4E,6E)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-
decadienoic acid (ADDA), D-Ala and D-methylaspartate. Cyclization is produced through the side chains 
of the two D-methylaspartates. Eighty microcystins have been identified to date, representing differences 
in two variable residues and some modifications in the other amino acids. Microcystin-LR is the most 
extensively studied and is named because it contains Leu and Arg occupying the variable residues of the 
peptide.  
A paradigmatic example of the development of synthetic cyclic peptides for therapeutic purposes 
comes from the design and synthesis of a series of RGD analogs targeting cell adhesion receptors. These 
cyclic analogs contain the fragment Arg-Gly-Asp (RGD) known to be a common element in cellular 
recognition and specifically, a binding epitope for membrane-bound integrins. Thus, by controlling the 
conformation of the ring and consequently that of the RGD motif, Kessler and collaborators [112, 113] 
were able to design and synthesize selective cyclic RGD peptides for the αIIbβ3 and for the αvβ3 
integrins. The former with applications as antithrombotic agent, whereas the latter as anticancer drug 
through the prevention of angiogenesis and by inducing apoptosis in vascular cells.  
Another interesting example of the use of a cyclic peptide designed to preserve the bioactive 
conformation of a larger peptide segment is exemplified in the story behind the discovery of somatostatin 
analogs. Based on the hypothesis that the tetrapeptide segment Phe7-Trp8-Lys9-Thr10 in somatostatin is 
involved in a β-turn in its bioactive form and that much of the remainder of the hormone apparently 
functions as scaffold, researchers at Merck found a somatostatin analog 1.24 times more active than 
somatostatin in a cell culture assay [114]. Using the structure of this compound as reference and after a 
careful molecular modeling study, a series of smaller cyclic hexapeptides up to 1.7 times more potent that 
somatostatin were design and synthesized [115].  
A more recent example is exemplified by the design of cyclic analogs of the α-melanocyte-
stimulating hormone (α-MSH) [116]. The hormone is a tridecapeptide of sequence Ac-Ser1-Tyr2-Ser3-
Met4-Glu5-His6-Phe7-Arg8-Trp9-Gly10-Lys11-Pro12-Val13-NH2, of which the tetrapeptide His6-Phe7-Arg8-Trp9 
forms the essential active core. With this idea in mind, there were synthesized several cyclic analogs that 
provide the tetrapeptide diverse conformations. The first cyclic analogs designed involved the replacement 
of Met4 and Gly10 by cysteine residues to form a disulfide bond. The compound is a potent analog but 
lacked prolonged biological potency. This compound was later improved with the discovery of MT-II with 
sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 (Nle = norleucine), a potent agonist with prolonged 
biological potency. Subsequent modifications of MT-II lead to design selective analogs to the diverse 
melanocortin receptors.  
As mentioned above, cyclization can also promote local conformational changes on a peptide. As 
an example, aiming at stabilizing a helical conformation, side chain-side chain cyclization between Glu30 
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and Lys33 in corticoprin-releasing factor through a lactam ring, played an important role in the discovery of 
astressin a potent corticoliberin 2 (CHR2) antagonists [117].  
Local Rigidification Using Conformationally Constrained Residues 
 A different approach to rigidify the structure of a peptide is the inclusion of conformationally 
constrained amino acids in the sequence. The inclusion of these amino acids aims to produce analogs 
with local conformational constraints which eventually exhibit improved affinities by diminishing the entropy 
cost occurred upon binding to their receptors. Constraints can be applied to the backbone or to the side 
chain dihedral angles [104]. The former induce a local modification on the structure of the peptide chain, 
whereas the latter are intended to block side chains in specific conformations. Proline is the only of the 
twenty natural amino acids with its backbone conformational space constrained due to the covalent bond 
between the side chain and the amine nitrogen. As a consequence the Φ angle is restricted to adopt 
values close to −60°. The cyclic structure also confers a low cis-trans isomerization barrier to the peptide 
bond preceding a proline in a polypeptide chain (20–22 kcal mol−1) [118]. Actually, this process constitutes 
one of the most widespread molecular switches in biochemical pathways and it is known to be the rate-
determining step in the folding [119] and denaturing of proteins [120]. Its conformational rigidity affects the 
secondary structure of proteins and may account for its higher prevalence in the proteins of thermophilic 
organisms. Proline acts as a structural disruptor in the middle of regular secondary structure elements 
such as alpha helices and beta sheets; however, it is commonly found in turns and as the first residue of 
an alpha helix and also in the edge strands of beta sheets [121]. A different way to induce a local constrain 
in the peptide backbone is through a α-substitution, in which the hydrogen of the Cα is substituted by an 
alkyl chain. One of the most important examples of this kind of residues is the α-aminoisobutyric acid also 
referred as methylalanine (Aib) 34 (Figure 3) found in transmembrane channel-forming peptide antibiotics 
known generically as peptaibiotics (peptide antibiotics with high Aib content) [122]. Dehydroalanine 35 
(Figure 3) also found in some natural non-ribosomally synthesized peptides represents a different way to 
constrain the backbone through a Cα-Cβ double bond. On the other hand, side chains can be constrained 
in different ways. For example, adding a substituent in Cβ makes the amino acid to exhibit an important 
constraint in its conformational space. Natural amino acids like valine, isoleucine or threonine exhibit a β-
substitution. Inspired by these constrained amino acids, a series of new amino acids with a limited 
availability of the conformational space have been designed in the last years.  
Cα,α-dialkylated amino acids represent one of the most widely studied families of non-coded amino 
acids [123]. These amino acids confer severe restrictions to the polypeptide chain through an important 
reduction of the conformational space available, favoring specific secondary structures. The most 
extensively investigated member of the family is Aib. The presence of a second methyl group at the Cα 
restricts the backbone conformational space available to the helical region with a higher propensity to form 
310 rather than α-helices [124]. Interestingly, the achiral nature of Aib permits the residue to participate in 
right- and left-handed helices with the same propensity. Accordingly, Aib plays an important role as helix 
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enhancer when inserted in a polypeptide chain, as has been observed both, in solution as well as in 
crystal structures [125]. Other members of the series exhibit differential conformational profiles. Thus, the 
achiral Cα,α-symmetrically disubstituted glycines, like in α-diethylglycine, α-di-n-propylglycine or α-di-n-
butylglycine tend to adopt C5 conformations stabilized by an intramolecular hydrogen bond, inducing the 
peptide backbone to adopt an extended conformation [126]. On the other hand, the achiral analogs exhibit 
a different profile. Isovaline, also referred as ethylalanine (Iva), the simplest achiral member of the family is 
a strong helix enhancer. Like Aib it is capable to participate in both right- and left-handed helical 
structures. However, due to the chirality of the Cα the two isomers exhibit a differential conformational 
behavior, with the D-Iva exhibiting a higher tendency to form left-handed helical structures [127], whereas 
L-Iva tends to favor right-handed ones [128]. In regard to the α-methyl derivatives of natural amino acids, 
they are strong inducers of β-turns or right-handed 310-helical structures depending on the chain length. 
Interestingly, those amino acids that are Cγ-branched like α-methylphenylalanine, α-methylleucine or α-
trptophan tend to generate the opposite screw sense of helicity [122].  
The two alkyl chains of Cα,α-dialkylated amino acids can be part of a ring. This gives rise to the 1-
amino-cycloalkane-1-carboxylic acids (Acnc) 36 (Figure 3), where n is the number of carbon atoms in the 
ring [129]. These amino acids induce almost exclusively helical conformations to the peptide chain [121]. 
The simplest one of the series is the 1-aminocyclopropanecarboxylic acid (Ac3c), naturally found in 
diverse compounds like in the nonadepsipeptide BZR-cotoxin II [129]. This depsipeptide is produced by 
fungus that causes leaf spot disease in corn. The insertion of Ac3c in a polypeptde chain produces 
interesting conformational restrictions. Indeed, inspection of its Ramachandran map suggests that this 
amino acid adopts as preferred conformation when φ is around±80° and ψ is around 0°, what makes an 
interesting residue to be in position i+2 of both type I and type II β-turns. In addition, the residue can also 
accommodate distorted type III bends and 310-helices [130].  
These residues have successfully been used to reduce the conformational freedom of diverse 
peptide ligands. Thus for example, in the search for sweeter compounds than the dipeptide L-Asp-Phe-
OMe (aspartame), diverse analogs were synthesized, being L-Asp-Ac3c-OMe 37 (Figure 5) a very active 
compound with a sweet taste of up to 300 times stronger than that of sucrose [131]. Another example is 
given by the analog L-Pro-L-Leu-Ac3cNH2 38 (Figure 5), where Ac3c substituted Gly, shows an increased 
binding affinity in regard to its parent compound to the dopamine D2 receptor, an effect which is 
postulated to be useful in the treatment of extrapyramidal motoric disorders such as Parkinson’s disease 
and depression [132]. Another example is represented by the acetyl derivative of the N-2(S)mercapto-3-
methyl-1-oxobutyl-Ac5c-Tyr (CGS 30440) 39 (Figure 5), a dual inhibitor of the neutral endopeptidase and 
the angiotensin-I converting enzyme that is clinically applied in the treatment of hypertension and 




Molecular diversity can be increased to the cyclic Cα,α-dialkylated amino acids by attaching 
substituents to the ring. Residues of this kind are found as natural products like (-)-coronamic acid 40 
(Figure 5) found in the plant toxin coronatine [134]. These amino acids preserve the conformational 
features of the corresponding parent compounds constraining the backbone chain locally and exhibit 
functional side chains. Moreover, side chains are also constrained, exhibiting defined values of the χ1 side 
chain angle forcing specific orientations of the corresponding functional groups. These amino acids have 
however the drawback that substituents normally add chiral centers to the molecule and consequently, 
require stereoselective synthesis [135]. The most extensively studied amino acids of this kind of amino 
acids are the derivatives of the twenty occurring amino acids and specially the phenylalanine derivatives 
due to the involvement of aromatic rings in intermolecular interactions in peptides. Thus for example, the 
amino acid produced by the attachment of a phenyl group to the cyclopropane cycle in Ac3c: the 1-
aminophenylcyclopropane-1-carboxylic acid (c3Phe) is a constrained phenylalanine that exhibits the 
aromatic ring in very specific conformations. There are four stereoisomers possible (2R,3S)-c3Phe 41; 
(2R,3R)-c3Phe 42; (2S,3S)-c3Phe 43 and (2S,3R)-c3Phe 44 (shown in Figure 5) that exhibit slightly 
different conformational propensities. This behavior can be seen in the four analogs of the peptide Ac-L-
Pro-c3Phe-NHMe adopt βΙ-type and β-II type turn conformations, however they exhibit a differential type 
I/type II proportion [136]. These amino acids have been used in many occasions to design more potent 
peptide analogs by restricting the conformational space available to conformations close to the bioactive 
form [137]. Thus for example, one of the stereoisomers of the analog Phe-c3Met-Arg-PheNH2 was shown 
to exhibit an improved anti-opiate activity in regard to the parent compound [138]. Amino acids with bulkier 
cycloalkane moieties have also be synthesized, like the adamantyl amino acid (2-aminoadamantane-2 
carboxylic acid) 45 (Figure 5). This amino acid has interesting properties like being resistant to proteolytic 
degradation and an helper of blood-brain-barried crossing, due to the bulkiness and hydrophobicity of its 
side chain. From the structural point of view adamantanine is a γ-turn inducer [139]. Although its use in 
drug design is limited, there are interesting examples of its use. This, for example the adamantyl amino 
acid is present as moiety in meclinertant 46 (Figure 5), the first a non-peptide antagonist found at the 
neurotensin receptor-1. The compound crosses the blood-brain-barrier and it is currently used to explore 
the interaction between neurotensin and other neurotransmitters in brain [140]. 
It can also be considered cyclic Cα,α-dialkylated amino acids that some of the atoms of the ring 
substituted by heteroatoms. These amino acids are interesting since in addition to constrain the peptide 
backbone, add certain functionality that can be useful in molecular recognition. Thus, for example a 
disulfur substituted Ac5c: the 4-amino-1,2-dithiolane-4-carboxylic acid 47 (Figure 5) is an excellent inhibitor 
of the synthesis of S-adenosyl-L-methionine a cofactor in various enzyme-catalyzed reactions of which 
transmethylation are the most significant [141].  
 
Another important group of non-coded residues conformationally constrained residues are the α,β-
dehydroamino acids (represented as ∆Xaa) 35 (Figure 3) whose distinctive feature is to have a double 
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bond between Cα and Cβ [142]. The simplest member of the family is the dehydroalanine (∆Ala) that is 
found together with dehydrobutyrine (∆Abu) in a class of antibiotics known as lantibiotics, including 
members like nisin, epidermin, and subtilin [143]. These peptides are ribosomally synthesized and 
subjected to posttranslationally modifications involving a two-step procedure in which selected threonine 
and serine residues are enzymatically dehydrated to form ∆Abu and ∆Ala respectively, followed by a 
stereoselective intramolecular Michael-type addition of Cys thiols to the newly formed dehydroamino acids 
to form sulfur-to-β–carbon thioether cross-links [144]. 
In regard to their structure, α,β-dehydroamino acids constrain the peptide backbone to adopt β-
turns in short sequences and helices in longer ones, as well as restrict the side chain in the E or Z 
position. As in the case of other non-natural amino acids they exhibit an enhanced proteolytic stability and 
due to their distinctive features have been used for the design of synthetic analogues. An interesting 
application is exemplified by the recent report of a small peptide of sequence Phe-Gly-Ala-∆Phe-Leu 
found to inhibit fibril formation of the human islet amyloid polypeptide, involved in the development of type 
2 Diabetes Mellitus [145], although, most of the current application are in the field of de novo design of 
antibiotics [146].  
An interesting group of amino acids that restrict the conformational freedom of a peptide chain are 
the 1-azacycloalkane-2-carboxylic acids, i.e. residues with a cyclic side chain and with the amino group 
forming part of the ring. This family of compounds is inspired by proline, the 2-is the pyrrolidinecarboxylic 
acid 48 (Figure 6) that is the five-member ring of the series. Other members of this series include the 2-
aziridinecarboxylic acid 49 (Figure 6), the analog with a three member ring; the 2-azetidinecarboxylic acid 
50 (Figure 6), the analog with a four member ring; or the 2-piperidinecarboxylic acid 51 (Figure 6) the 
analog with a six member cycle. It can also be thought of derivatives of β-proline [147]. For example, the 
analog of endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) with the phenyl β-proline derivative 4-phenylpyrrolidine-
3-carboxilic acid 52 (Figure 6) replacing proline is a potent opioid derivative with dual antinociceptive and 
antidepressant actions [148]. Moreover, rings can have substituents attached as well as heteroatoms. 
Indeed, there are several analogs of proline found in natural compounds as the result of posttranslational 
modifications of the residue. For example, the cis-4-methyl-L-proline was found in the hydrolysis of 
leucinostatine or the trans-4-hydroxy-L-proline was first found in hydrolysates of a sponge [146]. Synthetic 
proline analogs have been used for drug design like for example, the dimethyl derivative of the thioproline, 
the 5,5-dimethylthiazolidine-4-carboxylic acid 53 (Figure 6) is an amino acid that forms part of a potent 
inhibitor against plasmepsins, a group of aspartic proteases found in the lethal malarial parasite P. 
falciparum that are vital for its survival [149].  
Proline derivatives may also have a fused ring giving rise to bicyclic amino acids. Examples are the 
2-indolinecarboxylic acid 54 (Figure 6) or the tetrahydroisoquinoline-3-carboxylic acid (Tic) 55 (Figure 6). 
These amino acids have a restricted conformational space available: on the one hand, the backbone as in 
proline and on the other, the side chain dihedral χ1. For example, Tic has χ1 constrained to take only the 
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values +60º or -60º. Accordingly, these compounds should be considered as constrained phenylalanines. 
One successful example of the use of Tic for drug design is exemplified in the search for new angiotensin 
converting enzyme inhibitors. Replacement of proline with Tic in enapril 56 (Figure 6), led to quinapril 57 
(Figure 6) approved by the FDA in 1991 [150].  
Side chains can also be constrained via the introduction of substituents at the β-carbon and it is a 
simple strategy to synthesize constrained amino acids. These modifications do not perturb the backbone 
conformation much and still allow side chains certain flexibility. Actually, three of the twenty natural 
occurring amino acids including valine, isoleucine and threonine show β-disubstitutions. Other β-
substituted amino acids are also found in nature. For example, β-dimethylcysteine (penicillamine) 58 
(Figure 6) is a metabolite of penicillin. This amino acid has been used in the past to generate constrained 
peptides. Specifically, it was used to design the cyclic analog (D-Pen2,D-Pen5)-enkephalin (DPDPE), one 
of the most selective and potent opioid peptides interacting with the δ-receptor [151]. In regard to newly 
synthesized amino acids, both β-methyl and β-phenyl-substituted analogs of aromatic amino acids are the 
most extensively studied [152]. The effects of β-substitution on the biological properties of a peptide 
depend on the chirality of the stereoisomers. They have been useful in improving our knowledge of the 
features of the binding site of diverse receptors or discover more potent analogs. Thus, for example the 
features of the different β-methylphenylalanine 59 (Figure 6) isomers were used to ascertain the 
pharmacophoric features of the δ-opioid receptor [153]. Another interesting example is the use of β-
diphenylalanine 60 (Figure 6) for the discovery of a potent antibiotic enhancer [154]. 
Local Rigidification Using Dipeptide Mimetics 
As mentioned above, the ability of a peptide to adopt a turn at a specific position of the chain can 
be crucial to adopt its bioactive conformation necessary to interact with a specific receptor. This is 
particularly important in the case of peptide ligands of G-protein coupled receptors [155]. Dipeptide 
mimetics can be used to design molecules that mimic the conformational role of specific residues of the 
chain by introducing local restrictions on the peptide backbone. Once it is established through structure-
activity studies that a turn enhances peptide affinity, a step forward to design a peptidomimetic is to 
replace the residues involved in the turn by an organic scaffold. These dipeptide mimetics are designed 
with two reactive handles conveniently oriented in such a way that can be used to attach N- and C- 
terminal polypeptide chains, in addition to preserve the necessary side chains for an adequate interaction 
with the receptor.  
Cyclic lactams, known as Freidinger lactams after their discoverer, were one of the first dipeptide 
mimetics designed to mimic two consecutive residues involved in a β-turn [156]. Since then, cyclic lactams 
have been used thoroughly in the design of peptidomimetics [157]. This type of structures are found in 
natural products like penicillin G 61 (Figure 7), a potent antibiotic extracted from a fungus; dolastatin 13 62 
(Figure 7) a cytostatic depsipeptide isolated from a sea hare; or bengamides 63 (Figure 7), potent immune 
21 
 
modulating agents extracted from a bacterium and from a sponge, respectively. The idea to utilize 
dipeptide lactams as conformational constraints in peptides was originated in a study involving a series of 
C3 symmetric cyclic hexapeptides, exemplified by the analog (Ala-Sar)3 [158]. These peptides have cation 
binding properties and had been studied for their capacity to improve feed efficiency in ruminant animals 
by shifting ruminant stomach bacterial fermentation toward the production of less volatile products. A 
molecular modeling study of these cyclic peptides suggested that building a bridge from the Cα of alanine 
to the nitrogen of the succeeding sarcosine could be an effective way to constrain the ring 64 (Figure 7). 
The lactam ring can vary in size, ranging from a β-lactam resulting in a azetidinone ring; a γ-lactam for a 
five member ring resulting in a pyrrolidinone scaffold that can be considered to mimic a Gly-Ala dipeptide; 
a δ-lactam with a six member ring resulting in a piperidone scaffold that mimics a Ala-Ala dipeptide; a ε-
lactam with a seven member ring resulting in a azepanone scaffold or even larger as for example the 
azoninone ring proposed to design type II’ β-turns [159]. These series of substituted lactams offer a 
diversity of structures to mimic constrained dipeptides and can be expanded further by incorporating 
heteroatoms to the ring [160].  
Other heterocycles have also been used as scaffold for peptidomiemtic design [161]. Thus, in the 
case of the piperidone ring -the six member cyclic lactam- diverse modifications have been considered like 
the addition of a second nitrogen to the cycle, giving rise to the piperazinone ring 65 (Figure 7). This 
scaffold has been used in the past to design diverse constrained analogs such as peptidomimetics of the 
sequence CAAX, where X is usually leucine or phenylalanine, as potent inhibitors of the enzyme 
geranylgeranyltransferase for the treatment of cancer [162]. Adding a second ketone group to the 
piperidone ring generates the diketopiperidine scaffold 66 (Figure 7), a surrogate of the Ala-Gly dipeptide 
[163]; or to the piperazinone ring generates the diketopiperazine scaffold 67 (Figure 7) [164]. This latter, in 
addition to appear in diverse natural products like trypostatins, brevianamides, rosstratins A or 
vertihemiptellides [165], has been extensively used for new drug discovery. Examples include its use for 
the development of oxytocin antagonists [166] or as tubulin polymerizing agent with antitumor activity 
[167].  
In regard to seven-member rings there are also diverse scaffolds based on the corresponding 
cyclic lactone: azepanone. Thus, the incorporation of extra nitrogens to the ring generates diazepanones 
like 68 (Figure 7) [168] or cyclic ureas like 69 (Figure 7) [169] and triazepanones 70 (Figure 7) [170] that 
have been used as scaffold in peptidomimetic design with the purpose to mimic γ-turns. However, the 
most extensively seven member rings used are the diazepinones 71 (Figure 7) that exhibit the ring 
partially unsaturated. 
Freidinger lactams as well as other heterocycles can also be part of a bicyclic scaffold, opening the 
door to the design of a vast diversity of compounds [171, 172]. Ring annelation can be done through the 
addition of an aromatic ring to the cyclic lactam. These bicycles can be considered mimetics of the 
phenylalanylglycine dipeptide that hold the phenyl side chain oriented in the “anti” conformation (χ1 = 
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180°). For example, the benzoazepinone scaffold 72 (Figure 7) has been used for the design of potent 
and specific farnesyl transferase inhibitors [173]. An aromatic ring fused to a diazepinone generates the 
benzodiazepinone scaffold 73 (Figure 7), extensively used in peptidomimetic design. Thus for example, a 
benzothiazepine bicycle 74 (Figure 7) has been used for the development of potent angiotensin converting 
enzyme inhibitors [174]. Actually, this scaffold is well known in pharmacology since diverse analogs based 
on this scaffold belong to an exclusive class of drugs with anxiolytic profile that act as positive allosteric 
modulators of the inhibitory neurotransmitter GABA binding to the so-called benzodiazepine receptor 
[175].  
Cyclic lactams can also be set up using the skeleton of a proline residue giving rise to 
azabicycloalkane scaffolds 75 (Figure 7). Compounds with a six or seven member ring annealed to a 
proline skeleton have been used to rigidify the structure of peptide analogs, like the RGD analogs recently 
disclosed as potent integrin antagonists [176] or a set of analogs designed as thrombin inhibitors [177]. 
These bicyclic scaffolds can also be used to produce rings of diverse size, including diverse substituents 
and/or heteroatoms in the rings [172], or design from them more complicated structures. Thus for 
example, compound 76 (Figure 7) contains a benzoazabicycloalkane scaffold that mimics the dipeptide 
Phe-Leu, exhibiting a pharmacological profile as potent dual inhibitor of angiotensin converting enzyme 
and neutral endopeptidase 24.11 [178]. An alternative to these structures consists of the attachment of an 
additional ring to produce a spiroazabicycloalkane scaffold 77 (Figure 7). This scaffold has been used 
successfully in peptidomimetics of the Pro-Leu-GlyNH2 tripeptide as allosteric modulators of the dopamine 
D2 receptor [179]. It can be thought also in using a tricycle scaffold by closing a ring structure between two 
consecutive prolines. In this direction, the derived diketopiperazine template has successfully been used 
to design molecules that works as model receptors of tripeptides and that could be used 
pharmacologically as a non-competitive antagonist [180]. 
Other organic scaffolds designed to generate turns in a peptide chain have been used in the past. 
These scaffolds are inspired by the D-Pro-L-Pro dipeptide 78 (Figure 8), known to adopt a stable type II’-β 
turn [181] and designed to provide two reactive handles which can be used to attach N- and C- terminal 
polypeptide chains. Among them, the diketopiperazine incorporating a substituted proline 79 (Figure 8) 
has demonstrated to be a useful scaffold [182]. On the other hand, diverse biaryl scaffolds have been 
described in the literature including biphenyl 80 (Figure 8) [183]; diphenyltriazole 81 (Figure 8) [184]; 
dibenzofuran 82 (Figure 8) [185]; diphenylacetylene 83 (Figure 8) [186]; xanthene scaffolds 84 (Figure 8) 
[187]. Similarly, the condensed bicycles like naphthalene 85 (Figure 8) and quinoline 86 (Figure 8) have 
also been utilized in the design of HIV protease inhibitors [188]. Other strategy to design turn mimetics has 
been to attach two aromatic rings to a scaffolding molecule like urea. Thus, the dimethyldiphenylurea 87 
(Figure 8) has been used as template to design somatostatin analogs [189]. In the same direction, diurea 
scaffolds have been used to hold two β-strands forming a parallel β-sheet 88 (Figure 8) [190]. More 
recently an azobenzene scaffold 89 (Figure 8) has been used as template to synthesize cyclic 
somatostatin analogs [191]. This scaffold has the feature to change conformation upon light absorption. 
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So that, when it is in the cis conformation helps to the rest of the peptide chain to form a β-turn, whereas 
in the trans conformation the peptide segment does not acquire its bioactive conformation. Accordingly, 
this scaffold allows modulating the three-dimensional structure and biological activity upon light exposure.  
Designing Peptides and Peptidomimetics with Preferred Conformations other than Turns 
Natural amino acids exhibit differential preferences to adopt specific secondary structures due to 
the nature of their side chains. Obviously, this can also be extended to non-proteogenic amino acids 
widening the repertoire of possibilities to design peptide analogs with specific conformational preferences. 
Accordingly, a careful selection of a sequence together with a wise incorporation of unnatural amino acids 
in the polypeptide chain can help to enhance a specific secondary structure in an analog. In this direction, 
a great deal of interest has been devoted in the last years to develop procedures to synthesize analogs 
mimicking α-helices, β-sheets or hairpin turns [192]. The interest of designing sequences with a specific 
secondary structure is of great interest in drug design particularly, in protein-protein interactions. These 
molecules are aimed at mimicking protein epitopes with increased binding affinity of protein, avoid rapid 
degradation and eventually, to increase membrane permeability. Moreover, the interest of designing these 
molecules goes beyond the biomedical arena, being of great interest in the field of constructing artificial 
receptors or in a broader sense in nanotechnology, as a tool to construct structures for specific purposes 
[193].  
Helices are important structural elements in biomolecular recognition and have been focus of 
attention for many years. The main focus of interest in regard to drug design has pivoted around three 
different topics: helicity enhancement of natural ligands known to adopt helical structures; helicity 
enhancement of specific antimicrobial peptides, since this has been found to be a determining factor for 
antibiotic activity; and, the design of helical peptides or mimics acting as inhibitors of protein-protein 
interactions. Accordingly, there is an ample literature describing the design of helical peptides and 
peptidomimetics [194].  
In order to design helical peptides it should be taken into account that not all the 20 proteogenic 
amino acids exhibit the same propensity to adopt α-helices. Thus, it is known that Leu, Glu or Lys, as well 
as short stretches of alanine are strong stabilizers of this secondary structure [195]. In addition to make 
use of the tendency of natural residues to adopt a helical structure, several strategies have been used in 
the past to enhance peptide helicity [196]. The simplest procedure is to incorporate helicogenic residues to 
the sequence. Thus, Cα,α-dialkylated amino acids [197] as well as β-amino acids have been widely used 
for this purpose [198]. For example, a series of β-peptides have successfully been designed to mimic the 
helical peptide MDM2, a natural negative regulator of the tumor suppressor p53 for the treatment of breast 
cancer [199].  
When designing a peptide aimed at adopting a helical structure, careful attention needs to be given 
also to the edges of the helix. In fact, the N-terminus of a α-helix has four amide hydrogens lacking the 
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characteristic backbone hydrogen bond interactions and the C-terminus also has four free carbonyl 
groups. So, it is recommended to use appropriate residues before and after the helical segment (capping 
residues) in order to avoid unfavorable charge interactions with the helix dipole and with specific side 
chains and, to provide the possibility to form hydrogen bonds to those residues at the beginning or end of 
the helix in order to stabilize it. Amino acids like Asn, Asp, Ser, Thr, and Cys that can accept hydrogen 
bonds from otherwise free backbone NH groups exhibit the highest N-cap preference [200]. On the other 
hand, there is little variation in C-cap preference of the different amino acids apart from the widespread 
occurrence of Gly at this position due to its capability to adopt a left-handed conformation without an 
energy penalty [201]. In addition to the importance of capping residues for helix formation, there have 
been identified a few local motifs that stabilize the edges of the helix. At the N-terminus two motifs have 
been identified. The first, called capping box that involves a hydrogen bond the peptide bond amide and 
the side-chain of a Glu or Asp residues at position N3. The second, called hydrophobic staple, is the result 
of a hydrophobic interaction between the side-chains of two residues located at positions N’ (residue 
previous to the N-cap) and N4, plus a good capping residue. Moreover, the presence in phase of a 
hydrophobic staple and a capping box motif stabilizes strongly the helical conformation [202]. At the C 
terminus there is a motif identified for helix termination by Gly, called the Schellman motif, that consist of a 
Gly at position i; a hydrophobic residue at positions i - 4 and i + 1; and a polar or Ala residue at position i – 
2 [203]. However, although this motif is found in proteins it does not help helix formation of short peptides 
in solution [204]. Another local C-terminal motif found in α-helices the so-called Pro-capping motif, 
consisting in X-Pro pairs (with X= Asn, Cys, His, Phe, Tyr, Trp, Ile, Val and Leu), in which residue X is the 
C-cap and the Pro is a residue after [205]. 
A step further to enhance peptide helicity consists of cross-linking side chains of residues distant 
one helix turn. Thus the hydrogen bonding, charge-charge interaction or hydrophobic/aromatic interactions 
between residues lying on the same face of the helix has shown to be a good strategy. Moreover, this 
effect can be further reinforced through a chemical link using lactams, disulfides or metal ion coordination 
complexes among a variety of other linkages [206]. Thus for example, the use of side chain lactams in its 
N-terminus was pivotal in confirming the helical nature of the bioactive conformation of the Human 
Parathyroid Hormone [207]. Stabilization of α-helices can also be done through hydrocarbon cross links. 
The approach consists of incorporating covalent bonds of the type C=X-Y-N as surrogates of the helical i, 
i+4 hydrogen bonds. Specifically, the process requires the incorporation of amino acids with olefinic side 
chains in order to enable an intramolecular metathesis reaction to get a “stapled” helix [208, 209]. This 
approach produces peptides that in addition to have higher affinities than their templates, exhibit increased 
proteolytic instability and enhanced membrane permeability. This technique has been used to design 
diverse bioactive peptides concerning the treatment of cancer including inhibitors of Bcl-2 [210]; inhibitors 
of the tumor suppressor p53 [211]; the Notch transcription factor [212]; or the estrogen receptor [213].  
The procedure has been shown successful even for long helical peptide stretches. Thus for example a 
double-hydrocarbon stapled analog of the 36-amino acid peptide antiviral enfuvirtide described above, 
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exhibits a fourfold increased potency in comparison to its template and exhibits an improved 
pharmacokinetic profile, including oral absorption [214].  
Next step to mimic a helical ligand consists of using organic scaffolds capable to project key 
functional groups into the right directions. These mimetics can be classified into a wide group of molecules 
called scaffold mimetics that will be discussed in the following section [215]. 
β-strands are major secondary motifs that peptides adopt when bound to their receptors [85]. This 
structure is universally found in protease inhibitors [216] or in the of antigen to the major histocompatibility 
complex presentation process and it is also relevant to mimic some protein-protein interactions like those 
that occur in the so-called amyloid diseases, where β-strands could be useful is to interfere with 
peptide/protein β-strand aggregation [217]. Relatively few methods have been reported for fixing β-strand 
conformations to produce more potent ligands. Cyclization is a strategy to enhance this structure, either 
constraining the peptide in a macrocycle or to use side chain-side chain cyclization. Other strategies 
involve the replacement of a central peptide bond by an isostere that is flanked by peptidic or nonpeptidic 
appendages; or even replacement of the peptide backbone by an organic scaffold in such a way that 
relevant side chains can be directed properly, as will be discussed in the following section [218].  
Diverse macrocycles constructed by condensing peptide side chains to the main chain have been 
shown to produce highly constrained tri- and tetrapeptide sequences in an extended conformation [219]. A 
common cyclization scheme involves an ether link and a para substituted aromatic ring to form a 15-17 
member ring, like in compound 90 (Figure 9), a potent HIV protease inhibitor [220]. A more rigid cyclization 
scheme involves the use of a biphenyl ether scaffold to produce compounds like the angiotensin 
converting enzyme inhibitor K-13 (91 in Figure 9) [221] or the aminopeptidase B inhibitor OF4949-IV (92 in 
Figure 9) [222].  
In regard to non-cyclic β-strand mimics, there are many examples produced using isostere 
dipeptides that are flanked by peptidic or nonpeptidic appendages. Apart of those isosteres described 
previously, a 5-amino-2-methoxybenzoic acid combined with a 1,2-diaminoethane diurea molecular 
scaffold (93 in Figure 10) [223]; the 1,6-dihydro-3(2H)-pyridinone (94 in Figure 10) [224] or the 4,5-
dihydro-2(3H)-pyrazinone (95 in Figure 10) [225] have successfully been used for designing β-strands 
mimics.  
β-sheet is a major secondary structure motif found in proteins. It involves two β-strands interacting 
through a network of hydrogen bonds and hydrophobic interactions. When the β-strands run in the same 
direction the sheet is called parallel and anti-parallel when the two strands run in opposite directions. 
Analysis of the protein data base reveals that more than two thirds of two-stranded β-sheets are local in 
nature, forming β-hairpin turns [226]. It is considered that β-sheets play a major scaffolding role in protein 
architecture, and specifically β-hairpin turns are used as recognition epitopes for molecular recognition like 
in the hypervariable regions of antibodies or in some protein-protein and protein-DNA interactions [227].  
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β-hairpin formation depends on some combination of turn formation and cross-strand stabilization. 
Analysis of hairpin turns in the protein data bank reveals that the majority of loops found in proteins have 
five residues at the most. In the two-residue loops is most frequent to find reverse turns; in the three-
residue loops, residues 1 and 2 are often found adopting a type I β-turn and residue 3 is in the left-handed 
alpha-helical region; the four-residue loops often contain overlapping type I β-turn/310 helical segment. 
Loops with four and five residues with a proline residue exhibit a great propensity to adopt a cis peptide 
bond Xaa-Pro. In regard to the two strands it is important for peptidomimetic design to note that paired 
residues on opposite strands can exist at hydrogen-bonding and non-hydrogen bonding positions, being 
their side chains pointing to different sides of the hairpin, respectively.  
It is well established that both the turn sequence as the β-strands are important for the formation of 
a stable β-hairpin. So that the use of consensus β-turn sequences and β-turn mimetics which promote 
chain reversal and intramolecular hydrogen bonding does not guarantee to nucleate β-hairpin formation in 
sequences that are known to adopt this structure in proteins [228]. The reason of this is that both local 
conformational propensities and long-range interactions are required for β-sheet nucleation and that long-
range residue-residue side chain interactions appear to be much more important in β-sheet folding than in 
α-helix formation [229, 230]. Accordingly, the intrinsic β-sheet propensities of the amino acids in the 
strands are as important as the establishment of sidechain–sidechain interactions across the strands. 
Thus, the design of β-hairpins needs to be tackled using β-sheet amino acid formers such as valine, 
isoleucine and threonine or and, aromatic residues such as phenylalanine, tyrosine or tryptophan and 
using stable β-turns, whose conformation serves to form the first hydrogen bond of the β-hairpin and 
helps stitch together subsequent residues that register in hydrogen-bonding positions. These 
considerations permitted to design the first stable β-hairpins [231].  
Despite disulfide bonds between cysteine residues of adjacent strands in parallel β-sheets are rare 
among proteins, inter-strand disulfide bonds stabilize parallel β-sheets formed by an autonomously folding 
peptide in aqueous solution [232]. This strategy has been successfully used to design constrained peptide 
analogs like CVX15 a disulfide bond cross-linked β-hairpin peptide antagonist of the chemokine CXCR4 
receptor [233].  
A straightforward approach to design peptidomimetics of β-hairpin turns is using cyclic peptides 
[234]. These molecules are built by transplantation of the hairpin loop from a protein and stabilized using a 
constraining template like those described above. Interestingly, a convenient template used for 
macrocyclic β-hairpin mimetic design is the dipeptide D-Pro-L-Pro (78 in Figure 8), which itself is known to 
adopt a stable type II’ β-turn [181]. When incorporated into cyclic peptide the template nucleates β-hairpin 
conformations possessing the preferred right-handed twist typically observed between adjacent 
antiparallel β-strands in proteins.  
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Diverse β-turn mimetics have been used as constraining scaffolds in β-hairpin turn 
peptidomimetics [235] including dibenzofurans (80 in Figure 8) [185]; substituted diphenylacetylene (81 in 
Figure 8) [186]; diureas (86 in Figure 8) [189] or diketopiperazines incorporating substituted proline 
derivatives (79 in Figure 8) [182] using or not β-strand enhancers. 
The Biophysical Approach 
Scaffold Peptidomimetics 
As shown in Figure 1 a different approach to design peptidomimetics involves the use of scaffolds 
that hold the chemical moieties involved in ligand-receptor recognition (pharmacophoric groups), in the 
appropriate directions. Obviously, this approach implicitly assumes that only the side chains form part of 
the key interactions with the receptor. As we have shown above, this procedure has proven to be 
successful for designing peptidomimetics based on peptides that adopt different types of secondary 
structures [28].  
The idea of using an organic scaffold for peptidomimetic design was anticipated in the early 1980 
[236] and, the proof of concept was not reported until a few years later with the design of an enkephalin 
analog (96 Figure 10) [237]. Subsequently, β-D-glucose was successfully used to design peptidomimetics 
of somatostatin with agonistic profile like compound 97 (Figure 10) [238]. A process for the identification of 
suitable scaffolds was reported a few years later. In that study the spatial requirements of the side chains 
of β-turns were analyzed, providing criteria to select β-turn mimetic scaffolds [239]. This approach was 
further revised and extended to identify scaffolds suited for the synthesis of chemical libraries [240]. This 
method has been used to search for suitable scaffolds, among them the trans-pyrrolidine-3,4-
dicarboximide 98 (in Figure 10) [241]; oxopiperazines 99 (in Figure 10) [242] or spiroquinolines 100 (in 
Figure 10) [243].  
The concept of scaffold mimetics has also been used to design α-helix mimetics [212]. Specifically, 
the rationale of these peptidomimetics consists of finding a scaffold that can easily hold the functional 
groups of residues in positions i, i+3/i+4 and i+7. Several of such scaffolds have been described in the 
past including the terphenyl 101 (Figure 10) [244, 245]; terephtalamide 102 (Figure 10) [246]; biphenyl 
4,4’-dicarboxamide scaffolds 103 (Figure 10) [247] among others. There have also been described 
scaffolds capable to be used for the synthesis of combinatorial libraries. In this direction, the oligoamide 
derivatives [248] are very attractive scaffolds due to their synthetic accessibility via amide bond formation 
and predictable conformational profile. These scaffolds have been used successfully for the design of 
helical peptidomimetics. α-helix mimetics have also been designed using an organic scaffold that points 
the side chains in the right directions.  
Scaffold mimetics can also be used to mimic β-strands. They can be constructed using aromatic 
rings as spacers such as benzene; 1,5- or 1,6-naphtalene or biphenyl scaffolds. For example, in the quest 
for Ras farnesyltransferase inhibitors, several peptidomimetics of the peptide sequence Cys-Aaa-Aaa-X 
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(where Aaa represents an aliphatic amino acid and X=Met or Ser) in an extended conformation where 
designed using this strategy. Specifically, the potent farnesyltransferase inhibitors 104 (Figure 11) [249] 
and 105 (Figure 11) [250] contain a para-disubstituted phenyl group and a naphtyl group, respectively. 
The use of aromatic spacers for β-strand design has led to mimetics composed of alternating aryl and 
other functional groups like the imidazolidin-2-one rings, in such a way that are adapted to display diverse 
side-chains 106 (Figure 11 ) [251]. Much larger β-strand mimics have also been described in pioneering 
reports, such as the 2,8-diaminoepindolidione 107 (Figure 11) [252] or the polypyrrolinones 108 (Figure 
11) [253]. 
β-sheets constructs beyond β-hairpins are scarce. In fact, in some cases β-strand mimics are able 
to dimerize forming β-sheets. Specifically, the β-strand tripeptides mimic Hao 109 (Figure 11), comprising 
hydrazine, 5-amino-2-methoxybenzoic acid and oxalic acid groups dimerizes to form β-sheet constructs in 
noncompetitive organic solvents [254]. Linking Hao to the δ-amino group of the ornithine side chain 
through an amide bond produces the Orn(i-PrCO-Hao) scaffold 110 (Figure 11) that can be used to 
generate β-sheet constructs [255]. Using a different strategy, the tetrasubstituted diphenylacetylenes 111 
(Figure 11) [256] have successfully been used as direct linking spacer between two β-strands, permitting 
construct β-sheets avoiding the construction of a β-hairpin structure. 
Conclusions 
The present report aims to review different approaches described in the past to succeed in the 
process of designing peptidomimetics. Basically, there are two different approaches: a medicinal 
chemistry approach, where parts of the peptide are successively replaced by non-peptide moieties until 
getting a non-peptide molecule and a biophysical approach, where a hypothesis of the bioactive form of 
the peptide is sketched and peptidomimetics are designed based on hanging the appropriate chemical 
moieties on diverse scaffolds. The first is more traditional and has provided numerous peptidomimetics 
already in the market. From enzyme inhibitors like enapril and the recently developed HIV protease 
inhibitors among others to peptidomimetics of secretory peptides like losartan or icatibant among others. 
The second, it is getting momentum lately thanks to the quest for protein-protein interaction inhibitors, 
most of them mimics of protein epitopes. As an example, the recently approved venetoclax, a small 
molecule peptidomimetic of the Bak-BH3 peptide that enhances apoptosis through the inhibition of the Bcl-
xL protein for the treatment of chronic lymphocytic leukemia. 
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Table1. Results of the Ala scan on the hexadecapeptide Gly-Gln-Val-Gly-Arg-Gln-Leu-Ala-Ile-Ile-Gly-Asp-
Asp-Ile-Asn-Arg, a segment of the Bak-BH3 domain with inhibitory capacity of the protein Bcl-xL. Residues 
are represented with the one letter code [41].  
Peptide Sequence    KD (μM) 
GQVGRQLAIIGDDINR    0.34±0.03 
GQAGRQLAIIGDDINR     15±3 
GQVGAQLAIIGDDINR     3.3±1  
GQVGRQAAIIGDDINR    270±90 
GQVGRQLAAIGDDINR     1.0±0.2 
GQVGRQLAIAGDDINR     17±6 
GQVGRQLAIIADDINR    0.5±0.1 
GQVGRQLAIIGADINR    41± 4 
GQVGRQLAIIGDAINR    0.14±0.02 





Figure 1. Two different approaches to design peptidomimetics: a medicinal chemistry approach, where 
parts of the peptide are successively replaced by non-peptide moieties until a non-peptide molecule is 
obtained. Alternatively, there is a biophysical approach, where a hypothesis of the bioactive form of the 
peptide is sketched and a pharmacophore is developed. Peptidomimetics are designed based on the use 
of diverse scaffolds to attach different chemical moieties for pharmacophore fulfillment or are discovered 



























































Figure 11. Chemical structures of diverse secondary structure scaffolds. 
 
 
